Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 6/20 | 0.48 |
| ▸ | LATS2 | Q9NRM7 | 6/20 | 0.48 |
| ▸ | GPR6 | P46095 | 4/20 | 0.42 |
| ▸ | AOC1 | P19801 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15565354 | 0.81 | GLP1R (0.41) | LATS1LATS2GPR6GLP1RGRM5 | |
| SCHEMBL16818196 | 0.77 | LATS1 (0.50) | LATS1LATS2GLP1RL3MBTL1RXFP1 | |
| SCHEMBL29757578 | 0.76 | TDP1 (0.52) | LATS1LATS2AOC3KDM4E | |
| SCHEMBL2300291 | 0.76 | TDP1 (0.52) | LATS1LATS2AOC3KDM4E | |
| SCHEMBL16818216 | 0.74 | LATS1 (0.50) | LATS1LATS2GPR6 | |
| SCHEMBL15566766 | 0.74 | GPR6 (0.46) | LATS1LATS2GPR6KDM4ENPSR1 | |
| SCHEMBL15566370 | 0.73 | GPR6 (0.49) | LATS1LATS2GPR6 | |
| SCHEMBL17009592 | 0.73 | GPR6 (0.43) | GPR6GLP1R | |
| SCHEMBL15567266 | 0.72 | GLP1R (0.41) | GPR6GLP1RGRM5 | |
| SCHEMBL16818219 | 0.72 | CSNK2A2 (0.32) | GPR6KDM4ENPSR1L3MBTL1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738046-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-11 | — | — | US | disclosed |
| EP-3453709-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | Takeda Pharmaceutical Company Limited (JP) | 2019-03-13 | — | — | EP | disclosed |
| US-20180346464-A1 | SUBSTITUTED PYRIDO[3,4-b]PYRAZINES AS GPR6 MODULATORS | ENVOY THERAPEUTICS, INC. | 2018-12-06 | — | — | US | disclosed |
| EP-3083620-B1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-10077266-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-09-18 | — | — | US | disclosed |
| US-20170283414-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9708313-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20160031881-A1 | TETRAHYDROPYRIDOPYRAZINES AS MODULATORS OF GPR6 | ENVOY THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-9181249-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150175602-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175602-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | LATS1 1582/4885LATS2 1596/4885GPR6 1/4885 |
| US-20160031881-A1 | TETRAHYDROPYRIDOPYRAZINES AS MODULATORS OF GPR6 | GPR6, GPR65, GPR52 | LATS1 1801/4885LATS2 1772/4885GPR6 1/4885 |
| US-20180346464-A1 | SUBSTITUTED PYRIDO[3,4-b]PYRAZINES AS GPR6 MODULATORS | GPR6, GPR65, GPR55 | LATS1 2609/4885LATS2 2358/4885GPR6 1/4885 |
| US-10077266-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | GPR6, GPR65, GPR55 | LATS1 2609/4885LATS2 2358/4885GPR6 1/4885 |
| US-10738046-B2 | Substituted pyrido[3,4-b]pyrazines as GPR6 modulators | GPR6, GPR65, GPR55 | LATS1 2609/4885LATS2 2358/4885GPR6 1/4885 |
| US-20170283414-A1 | TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6 | GPR6, GPR52, GPR65 | LATS1 1582/4885LATS2 1596/4885GPR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.